15 Feb 2024 • The investigational combination of cefepime–taniborbactam has demonstrated superior efficacy over meropenem in treating complicated UTIs, including acute pyelonephritis.

Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor combination with activity against Enterobacterales species and P. aeruginosa expressing serine and metallo-β-lactamases.

Cefepime–taniborbactam achieved a composite success of 70.6%, surpassing meropenem at 58.0% in the intention-to-treat group. This advantage persisted even at late follow-up (days 28-35) with a safety profile comparable to meropenem.

Source: NEJM | Read full story